Ofer Shpilberg

22.7k total citations · 3 hit papers
261 papers, 9.2k citations indexed

About

Ofer Shpilberg is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Ofer Shpilberg has authored 261 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 86 papers in Oncology and 73 papers in Pathology and Forensic Medicine. Recurrent topics in Ofer Shpilberg's work include Lymphoma Diagnosis and Treatment (70 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Multiple Myeloma Research and Treatments (33 papers). Ofer Shpilberg is often cited by papers focused on Lymphoma Diagnosis and Treatment (70 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Multiple Myeloma Research and Treatments (33 papers). Ofer Shpilberg collaborates with scholars based in Israel, United States and Germany. Ofer Shpilberg's co-authors include Anat Gafter‐Gvili, Pia Raanani, Liat Vidal, Isaac Ben‐Bassat, Leonard Leibovici, Ron Ram, Mical Paul, Marek Trněný, Craig H. Moskowitz and Christian Gisselbrecht and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Circulation.

In The Last Decade

Ofer Shpilberg

257 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

2010 1.1k citations Christian Gisselbrecht, Bertram Glaß et al. Journal of Clinical Oncology profile →
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

1997 993 citations Ofer Shpilberg et al. Journal of Clinical Oncology profile →
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 412 citations Ofer Shpilberg et al. profile →

Peers

Countries citing papers authored by Ofer Shpilberg

Since Specialization

Citations

This map shows the geographic impact of Ofer Shpilberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofer Shpilberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofer Shpilberg more than expected).

Fields of papers citing papers by Ofer Shpilberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofer Shpilberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofer Shpilberg. The network helps show where Ofer Shpilberg may publish in the future.

Co-authorship network of co-authors of Ofer Shpilberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ofer Shpilberg. A scholar is included among the top collaborators of Ofer Shpilberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ofer Shpilberg. Ofer Shpilberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The molecular landscape of AL amyloidosis 2025 ·British Journal of Haematology ·(unknown), Eli Muchtar, Angela Dispenzieri, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah	0
2	Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia 2025 ·Scientific Reports ·(unknown), (unknown), Adi Zipin‐Roitman, (unknown), (unknown), (unknown), Dror Tobi, Andrii Bazylevich, Ofer Shpilberg, Michael Milyavsky, Oshrat Hershkovitz‐Rokah, Gary Gellerman	1
3	The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms 2024 ·Leukemia ·Mali Salmon‐Divon, (unknown), Ofer Shpilberg, Elimelech Okon, Jamal Benhamida, Mariko Yabe, Kseniya Petrova‐Drus, (unknown), (unknown), Roei David Mazor, Benjamin H. Durham, Julien Haroche, Omar Abdel‐Wahab, Eli L. Diamond, Oshrat Hershkovitz‐Rokah	2
4	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation 2021 ·Leukemia & lymphoma ·Oren Pasvolsky, Liat Shargian, Uri Rozovski, Ofir Wolach, Ron Ram, Michael Y. Shapira, Batia Avni, Polina Stepensky, Moshe Israeli, (unknown), Ofer Shpilberg, Pia Raanani, Moshe Yeshurun	5
5	A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma 2014 ·British Journal of Haematology ·Francine M. Foss, Ranjana H. Advani, Madeleine Duvic, Kenneth B. Hymes, Tanin Intragumtornchai, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, Robert J. Belt, Eric D. Jacobsen, Guy Laurent, Dina Ben‐Yehuda, M. Beylot‐Barry, Uwe Hillen, Poul Knoblauch, Gajanan Bhat, Shanta Chawla, Lee F. Allen, Brad Pohlman	161
6	First line and salvage therapy with total therapy 3-based treatment for multiple myeloma––An extended single center experience 2014 ·Leukemia Research ·Eli Muchtar, Ron Ram, Pia Raanani, Moshe Yeshurun, (unknown), Ofer Shpilberg, Hila Magen	10
7	Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase 2013 ·British Journal of Cancer ·Ofer Shpilberg, Christian Jackisch	106
8	Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure 2013 ·Leukemia Research ·(unknown), Galit Granot, Oshrat Hershkovitz‐Rokah, Jennifer Park, Ofer Shpilberg, Pia Raanani	6
9	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma 2012 ·Journal of Clinical Oncology ·Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vídriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Deborah Ricci, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau	58
10	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era breakdown → 2010 ·Journal of Clinical Oncology ·Christian Gisselbrecht, Bertram Glaß, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg, Dávid Ma, Josette Brière, Craig H. Moskowitz, Norbert Schmitz	1117
11	Management of adult patients with acute lymphoblastic leukemia in first complete remission 2010 ·Cancer ·Ron Ram, Anat Gafter‐Gvili, Liat Vidal, Mical Paul, Isaac Ben‐Bassat, Ofer Shpilberg, Pia Raanani	53
12	Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm) 2008 ·Antonio Palumbo, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Meletios Α. Dimopoulos, Martin Kropff, Ivan Špıčka, MT Petrucci, Michel Delforge, MV Mateos, Dixie‐Lee Esseltine, (unknown), William Deraedt, H. Van de Velde, Paul G. Richardson, (unknown)	7
13	Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis 2008 ·Journal of Clinical Oncology ·Pia Raanani, Anat Gafter‐Gvili, Mical Paul, Isaac Ben‐Bassat, Leonard Leibovici, Ofer Shpilberg	107
14	A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation 2007 ·APOPTOSIS ·(unknown), (unknown), Ofer Shpilberg, (unknown), (unknown), Ilana Nathan	31
15	Expression of CD24 on CD19−CD79a+ early B-cell progenitors in human bone marrow 2005 ·Cellular Immunology ·(unknown), Joseph Kapelushnik, Tikva Yermiahu, Itai Levi, (unknown), Ofer Shpilberg, George Shubinsky	14
16	Involvement of Proteases in the Action of IFN- γ on WISH Cells 2002 ·Journal of Interferon & Cytokine Research ·(unknown), Alexander Dvilansky, Ofer Shpilberg, Ilana Nathan	3
17	Measles antibody prevalence rates among young adults in Israel 2002 ·American Journal of Infection Control ·Michael Gdalevich, Guy Robin, Daniel Mimouni, Itamar Grotto, Ofer Shpilberg, Isaac Ashkenazi	13
18	Helicobacter pylori infection and subsequent peptic duodenal disease among young adults 2000 ·International Journal of Epidemiology ·Michael Gdalevich, Dani Cohen, Isaac Ashkenazi, Daniel Mimouni, Ofer Shpilberg, Jeremy D. Kark	4
19	Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine 1999 ·Leukemia Research ·Pia Raanani, Ofer Shpilberg, Shmuel Gillis, Abraham Avigdor, Izhar Hardan, Miriam Berkowicz, (unknown), Izidore S. Lossos, Angela Chetrit, Dina Ben‐Yehuda, Isaac Ben‐Bassat	12
20	Familial aggregation of haematological neoplasms: a controlled study 1994 ·British Journal of Haematology ·Ofer Shpilberg, Michaela Modan, Baruch Modan, Angela Chetrit, Z Fuchs, Bracha Ramot	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact